Phase II Clinical Trial Definition & Meaning | Health Care Term | CSIMarket
CSI Market
Sign In | Register

Glossary

Phase II Clinical Trial

Health Care Term

Phase II clinical trial is a type of clinical trial that is conducted after a successful Phase I clinical trial. It involves a larger group of patients who have the disease or condition being studied. The objective of Phase II clinical trials is to determine the safety and efficacy of the drug or treatment being studied.

In Phase II clinical trials, the drug or treatment is given to a larger group of patients, usually between 100 and 300 people, to further evaluate its safety and to determine its effectiveness in treating the disease or condition. Patients are closely monitored for any adverse effects and the medication is administered at different doses to identify the most effective dose.

The results of Phase II clinical trials can provide valuable information about the safety and efficacy of a new medication, and help researchers determine whether the drug should proceed to Phase III trials, or if further study is necessary.

In the healthcare industry, Phase II clinical trials are important for developing new drugs and treatments that can improve patient care. These trials are typically sponsored by pharmaceutical companies or research organizations, and are conducted in accordance with strict ethical and regulatory guidelines.

Overall, Phase II clinical trials play a critical role in advancing medical knowledge and improving patient outcomes by providing valuable data about the safety and efficacy of new drugs and treatments.


More Glossary Terms Beginning with P
  • Paediatric Exclusivity
    means, in the US, a six-month period of exclusivity to market a drug which is awarded by the FDA in return for certain paediatric clinical studies using that drug. This six-month period runs from the date of relevant patent expiry.
    Health Care Term Letter: P
  • Paid Development Method
    An actuarial method to estimate ultimate losses for a given cohort of claims such as an accident year/product line component. If the paid-to-date losses are then subtracted from the estimated ultimate losses, the result is an indication of the unpaid losses. The basic premise of the method is that cumulative paid losses for a given cohort of claims will grow in a stable, predictable pattern from y
    Insurance Term Letter: P
  • Panelboards
    Oriented strand board, particleboard, medium density fibreboard and plywood. Operating Statistics
    Manufacturing Term Letter: P
  • Partial Remission PR
    A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
    Health Care Term Letter: P
  • Particleboard
    A panelboard produced by chemically bonding clean sawdust, small wood particles and recycled wood fibre under heat and pressure. Forestry & Wood Products Industry Operating Statistics
    Manufacturing Term Letter: P
  • Particulate Matter
    Total suspended particulate. A measure of the solid particles (wood, process dust and smoke) found in air emissions.
    Manufacturing Term Letter: P
  • Particulates
    Tiny particles of a substance.
    Manufacturing Term Letter: P
  • Passenger Load Factor
    Represents the total number of seats sold as a percentage of total seat capacity on all sectors flown. Airline Industry
    Transportation Term Letter: P
  • Passenger Mile Yield
    The amount of passenger revenue earned per revenue passenger mile during a reporting period Airline Industry
    Transportation Term Letter: P
  • Passenger revenue yield per Mile Average Yield per RPM
    Represents the average scheduled passenger fare revenue for each revenue passenger mile (RPM), or each mile a scheduled revenue passenger is flown. Airline Industry
    Transportation Term Letter: P
  • Passive Immunotherapy
    Immunologically active material transferred into the patient as a passive recipient. Monoclonal antibodies are considered Passive Immunotherapy since antibodies are generated outside the body and given to the patient
    Health Care Term Letter: P
  • Patent Term Extension
    means an extension of up to five years in the term of a US patent relating to a drug which compensates for delays in marketing resulting from the need to obtain FDA approval.
    Health Care Term Letter: P